Transcenta Holding Limited (6628.HK)

1,520 +0,020 (+1,33%) Al cierre: 04:08PM HKT

Transcenta Holding Limited

B6-501, 218 Xinghu Street
Biobay
Suzhou 215123
China
86 21 6237 0929
https://www.transcenta.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 215

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Xueming Qian Ph.D.	CEO & Executive Chairman	3,5M	N/A	1969
Mr. Xiaolu Weng CPA	Executive VP & CFO	3,73M	N/A	1977
Dr. Feng Ye Ph.D.	Executive VP & COO	N/A	N/A	1969
Dr. Christopher Hwang Ph.D.	Executive VP & CTO	N/A	N/A	1965
Ms. Wei Wang	VP of Investor Relations & Capital Markets Department and Secretary to the Board	N/A	N/A	1983
Dr. Yi Gu Ph.D.	Senior VP & Head of Research	N/A	N/A	1969
Dr. Charlie Qi M.D.	Senior Vice President of Global Clinical Development	N/A	N/A	N/A
Dr. Xichen Zhang Ph.D.	Senior Vice President of Manufacturing	N/A	N/A	N/A
Dr. Wen-I Chang Ph.D.	Senior Vice President of Oncology Franchise Strategy	N/A	N/A	N/A
Dr. Caroline Germa M.D., Ph.D.	Executive VP of Global Medicine Development & Chief Medical Officer	N/A	N/A	1972

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en HKD.

Descripción

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST005, a PD-L1/TGF-ß bi-functional protein candidate for solid tumors; TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing; TST003, a regulatory protein expressed by stromal cells and tumor cells, including colon, prostate, gastric, lung, esophageal, pancreatic, and breast cancers; TST006, a bi-specific claudin 18.2/PD-L1 antibody for solid tumors; TST008, a bi-functional antibody for MASP-2 and BAFF for autoimmune diseases; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors; MSB2311, A humanized PD-L1 mAb candidate for solid tumors; TST012 and TST013, an ADC candidate targeting biomarker expressing gastric cancer and other solid tumors; and TST801, a bifunctional fusion protein for autoimmune diseases. The company has a partnership and collaboration agreements with Bristol Myers Squibb and Eli Lilly & Company; research collaboration with Alebund Pharmaceuticals, Dana Farber Cancer Institute, and John Hopkins University; and technology collaboration with Merck KGaA. The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019. Transcenta Holding Limited was incorporated in 2010 and is headquartered in Suzhou, the People's Republic of China.

Gobierno corporativo

El ISS Governance QualityScore de Transcenta Holding Limited, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.